BioLight
Innovation in Ophthalmology
We are an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome, or DES, and age-related macular degeneration, or AMD. Our current products and product candidates are designed to address a number of significant unmet medical needs of large and growing patient populations related to these ophthalmic conditions, by reducing patient non-compliance with drug therapy administration, improving efficacy and safety of treatment, offering better diagnosis and optimizing delivery of medications.
Leading key investors, holding about 60% of BioLight’s issued and outstanding shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India’s largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel and Rock One A Hong Kong investment based company.
BioLight is a public traded company on the Tel-Aviv Stock Exchange (BOLT).
News
Company’s Special Shareholders’ meeting
1 March 2021
BioLight reports investment agreement and a manufacturing agreement in the subsidiary DiagnosTear
29 October 2020
25 June 2020
21 June 2020
Annual General meeting of the shareholders of the Company, July 23, 2020
17 June 2020
DiagnosTear Ltd. – Approval to register patent to its TeaRx™ technology by the Israeli Patent Office
12 April 2020
Company’s Special Shareholders’ meeting, Wednesday May 23, 2020
5 April 2020
Company’s Special Shareholders’ meeting, Wednesday March 25, 2020
19 February 2020
22 December 2019
15 October 2019